Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31189953 | 0.87 | ALDH1A1 (0.69) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL3443973 | 0.87 | ALDH1A1 (0.69) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL941445 | 0.87 | GAA (0.56) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL24125014 | 0.86 | ALDH1A1 (0.72) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL352186 | 0.86 | ALDH1A1 (0.68) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL4654077 | 0.85 | GAA (0.76) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL27751925 | 0.84 | ALDH1A1 (0.65) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL4724873 | 0.84 | ALDH1A1 (0.73) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL1466699 | 0.83 | GAA (1.00) | GAAALDH1A1MAPTPKMLMNA | |
| SCHEMBL7341640 | 0.83 | ALDH1A1 (0.71) | GAAALDH1A1MAPTPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | claimed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | claimed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | claimed |
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | claimed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | claimed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | claimed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | claimed |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| EP-4590673-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4543892-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024061853-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| CN-117567450-A | Oxazolone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023247666-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-1229027-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229037-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229028-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-5811427-A | FUNGICIDES; CONTROLLING PHYTOPATHOGENIC FUNGI PARTICULARLY OF THE CLASS OOMYCETES | ROHM AND HAAS COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0816348-A1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | ROHM AND HAAS COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | NOD2, BAK1, CASP3 | GAA 2502/4885ALDH1A1 3885/4885MAPT 4108/4885 |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | GAA 2502/4885ALDH1A1 3885/4885MAPT 4108/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | GAA 2813/4885ALDH1A1 4353/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.